Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Oncology
Broxine Scheduled for December FDA Advisory Panel Meeting
November 24th, 1997
NeoPharm, Inc., Lake Forest, Illinois, announced that the U.S. Food and Drug Administration (FDA) has scheduled the company's New Drug Application (NDA) for Broxine (broxuridine) for review by the FDA's Oncologic Drugs Advisory Committee on December 19, 1997. The company submitted the NDA on December 27, 1996 for clearance to market the drug in the United States. Broxine is being developed for use as an in vivo prognostic test to measure tumor cell proliferation in breast cancer. This article was prepared by Cancer Weekly Plus editors from staff and other reports. Copyright 1997, Cancer Weekly Plus via NewsRx.com.
Source: Cancer Weekly (1997-11-24)
|
